✦ LIBER ✦

Anti-tumor necrosis factor therapy does not diminish the immune response to influenza vaccine in Japanese patients with rheumatoid arthritis

✍ Scribed by Tetsuo Kubota; Tokiko Nii; Toshihiro Nanki; Hitoshi Kohsaka; Masayoshi Harigai; Yukiko Komano; Takahiko Sugihara; Yoshinori Nonomura; Wataru Hirose; Kenji Nagasaka; Tetsushi Sakurai; Nobuyuki Miyasaka

Publisher: Springer
Year: 2007
Tongue: English
Weight: 240 KB
Volume: 17
Category: Article
ISSN: 1439-7595
DOI: 10.1007/s10165-007-0632-5

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Power doppler ultrasonographic monitorin

Power doppler ultrasonographic monitoring of response to anti–tumor necrosis factor therapy in patients with rheumatoid arthritis

✍ Esperanza Naredo; Ingrid Möller; Ana Cruz; Loreto Carmona; Jesüs Garrido 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 219 KB 👁 2 views

Decrease in the levels of anti-cyclic ci

Decrease in the levels of anti-cyclic citrullinated peptide antibody in Japanese patients with rheumatoid arthritis who responded to anti-tumor necrosis factor-α

✍ Sachiko Onishi; Taku Yoshio; Takao Nagashima; Seiji Minota 📂 Article 📅 2010 🏛 Springer 🌐 English ⚖ 167 KB

B cell depletion may be more effective t

B cell depletion may be more effective than switching to an alternative anti–tumor necrosis factor agent in rheumatoid arthritis patients with inadequate response to anti–tumor necrosis factor agents

✍ Axel Finckh; Adrian Ciurea; Laure Brulhart; Diego Kyburz; Burkhard Möller; Silvi 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 199 KB 👁 2 views

## Abstract ## Objective Patients with rheumatoid arthritis (RA) in whom the response to anti–tumor necrosis factor (anti‐TNF) therapy is inadequate have several therapeutic options, such as switching to an alternative anti‐TNF agent or initiating B cell–depleting therapy with rituximab (RTX). Alt

Cancer risk in patients with rheumatoid

Cancer risk in patients with rheumatoid arthritis treated with anti–tumor necrosis factor α therapies: Does the risk change with the time since start of treatment?

✍ Johan Askling; Ronald F. van Vollenhoven; Fredrik Granath; Pauline Raaschou; C. 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 99 KB 👁 3 views

An alternative, autonomic rationale for

An alternative, autonomic rationale for decreased risk of myocardial infarction in patients with rheumatoid arthritis responsive to anti–tumor necrosis factor therapy: Comment on the article by Dixon et al

✍ Andrew J. Holman 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 32 KB 👁 2 views

Replication of association of the PTPRC

Replication of association of the PTPRC gene with response to anti–tumor necrosis factor therapy in a large UK cohort

✍ Darren Plant; Rita Prajapati; Kimme L. Hyrich; Ann W. Morgan; Anthony G. Wilson; 📂 Article 📅 2012 🏛 John Wiley and Sons 🌐 English ⚖ 77 KB 👁 3 views

## Objective Several rheumatoid arthritis (RA) susceptibility variants map close to genes involved in the tumor necrosis factor (TNF) signaling pathway, prompting the investigation of RA susceptibility variants in studies of predictors of response to TNF blockade. Based on a previously reported ass